Rezafungin

CHEMBL3989945 Phase 4 Aprobado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1226.4 g/mol

LogP

2.9

Phase

4

Rezafungin is a novel long-acting echinocandin antifungal agent that inhibits beta-1,3-D-glucan synthase, an enzyme essential for fungal cell wall biosynthesis, disrupting cell wall integrity and causing osmotic instability and fungal cell death. Its extended half-life allows once-weekly intravenous dosing, distinguishing it from other echinocandins, and it has activity against Candida species including fluconazole-resistant strains and Pneumocystis jirovecii.

Peso molecular

1226,4000 g/mol

LogP

2,90

TPSA

366,00 Å²

Regla de cinco de Lipinski

No cumple

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estructura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

CCCCCOc1ccc(-c2ccc(-c3ccc(C(=O)N[C@H]4C[C@@H](O)[C@@H](OCC[N+](C)(C)C)NC(=O)[C@@H]5[C@@H](O)[C@@H](C)CN5C(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@H](O)[C@@H](O)c5ccc(O)cc5)NC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@H]([C@@H](C)O)NC4=O)cc3)cc2)cc1

InChI

InChI=1S/C63H84N8O17/c1-8-9-10-28-87-45-25-21-40(22-26-45)38-13-11-37(12-14-38)39-15-17-42(18-16-39)56(80)64-46-31-48(76)61(88-29-27-71(5,6)7)68-60(84)52-53(77)34(2)32-70(52)63(86)50(36(4)73)66-59(83)51(55(79)54(78)41-19-23-43(74)24-20-41)67-58(82)47-30-44(75)33-69(47)62(85)49(35(3)72)65-57(46)81/h11-26,34-36,44,46-55,61,72-73,75-79H,8-10,27-33H2,1-7H3,(H5-,64,65,66,67,68,74,80,81,82,83,84)/p+1/t34-,35+,36+,44+,46-,47-,48+,49-,50-,51-,52-,53-,54-,55-,61+/m0/s1

Molecular Formula

C63H85N8O17+

HBD / HBA

13 / 17

Enlaces Rotables

18

Átomos Pesados

88

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Preguntas frecuentes

Rezafungin is a novel long-acting echinocandin antifungal agent that inhibits beta-1,3-D-glucan synthase, an enzyme essential for fungal cell wall biosynthesis, disrupting cell wall integrity and causing osmotic instability and fungal cell death. Its extended half-life allows once-weekly intravenous dosing, distinguishing it from other echinocandins, and it has activity against Candida species including fluconazole-resistant strains and Pneumocystis jirovecii.

Yes, Rezafungin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3989945. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 78318119. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

¿Busca información accesible para el paciente?

Rezafungin en PillFYI

Estructura

Datos Rápidos

Fórmula: C63H85N8O17+
Sinónimos: 1

Enlaces externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.